# SciRhom

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scirhom

- Industry: Biotechnology
- Headquarters: Planegg, Germany
- Website: www.scirhom.com
- Total disclosed funding: $67M
- Latest round: Series A (Jun 26, 2024)
- Investors on record: 11

## About

Based in Planegg, Germany, SciRhom GmbH focuses on the development of innovative therapeutic antibodies aimed at targeting iRhom2, contributing to advancements in treatments for autoimmune diseases.SciRhom GmbH, founded in 2016 in Planegg, Germany, specializes in creating therapeutic antibodies targeting iRhom2, an upstream regulator of TACE. The company has completed 2 deals, with the latest funding round being a Series A, raising EUR 63.000 mn on June 26, 2024, led by new investors including Andera Partners and Kurma Partners. Jan Poth serves as the CEO.SciRhom GmbH develops innovative therapeutic antibodies specifically targeting iRhom2, a key regulator of inflammatory signaling through TACE. Their leading products are first-in-class humanized antibodies aimed at reducing inflammatory responses associated with conditions like rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis. These products are primarily marketed in Europe and North America, where they are prescribed by healthcare providers to patients suffering from autoimmune diseases.SciRhom GmbH generates revenue through strategic partnerships and licensing agreements within the biopharmaceutical industry, focusing on the development and commercialization of its anti-iRhom2 therapeutic antibodies. Revenue is expected from milestone payments linked to clinical development progress and subsequent direct sales to healthcare providers and hospitals upon product approval.Following the recent Series A funding of EUR 63.000 mn raised on June 26, 2024, SciRhom GmbH intends to enhance its clinical program's development. The company aims to expand its product offerings by launching new therapeutic antibodies and targeting additional markets in North America and Europe by 2025. The funding will play a crucial role in advancing their clinical trials and accelerating the commercialization of their innovative therapies.

## Funding rounds

- Series A, Jun 26, 2024, $67M — Wellington Partners, Andera Partners, Kurma Partners, High-Tech Gruenderfonds, MIG Capital, Bayern Kapital, Hadean Ventures, PhiFund Ventures, ELBE Beteiligungsgesellschaft mbH, F.E.L. Invest GmbH, BEAM Private Equity AG

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series A
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Series A
- Hadean Ventures (https://capitalatlas.ai/funds/hadean-ventures) — Series A
- PhiFund Ventures (https://capitalatlas.ai/funds/phifund-ventures) — Series A
- ELBE Beteiligungsgesellschaft mbH — Series A
- F.E.L. Invest GmbH — Series A
- BEAM Private Equity AG — Series A